Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 08 2024 - 8:00AM
Jnana Therapeutics, a clinical-stage biotechnology company
leveraging its next-generation chemoproteomics platform to discover
medicines for challenging-to-drug targets, today announced that
Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will
present a corporate overview at the RBC Capital Markets Global
Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m. ET.
About Jnana TherapeuticsJnana Therapeutics is a
clinical-stage biotechnology company leveraging its next-generation
RAPID chemoproteomics platform to discover medicines for highly
validated, challenging-to-drug targets to treat diseases with high
unmet needs. Jnana is focused on developing first- and
best-in-class therapies to treat a wide range of diseases,
including rare diseases and immune-mediated diseases. Jnana’s
wholly owned lead program, JNT-517, which targets an allosteric
site on the phenylalanine transporter SLC6A19, is a potential
first-in-class oral approach for the treatment of PKU, a rare
genetic metabolic disease. Located in Boston, Jnana brings together
scientific leaders in small molecule drug discovery and
development, a highly experienced management team, and the backing
of leading life science investors Bain Capital Life Sciences, RA
Capital Management, Polaris Partners, Versant Ventures, Avalon
Ventures, Pfizer Ventures, and AbbVie Ventures. For more
information, please visit https://www.jnanatx.com/ and follow us on
Twitter/X and LinkedIn.
Investor Contact
Josh Rappaport
Stern Investor Relations, Inc.
ir@jnanatx.com
Media Contact
Adam Silverstein
Scient PR
adam@scientpr.com